Quick Answer
Indaptus Therapeutics, Inc. reported Research And Development Expense of $9.34 million for the year ending 2025.
- Indaptus Therapeutics, Inc. showed an increase of +28.8% in Research And Development Expense from 2024 to 2025.
- This data is from Indaptus Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $1.28 million | Q3 2020: $1.35 million | Q1 2021: $489.7 thousand | Q2 2021: $391.1 thousand | Q3 2021: $697.7 thousand | Q1 2022: $1.30 million | Q2 2022: $1.51 million | Q3 2022: $1.61 million | Q1 2023: $1.88 million | Q2 2023: $1.48 million | Q3 2023: $2.23 million | Q1 2024: $1.59 million | Q2 2024: $1.71 million | Q3 2024: $1.47 million | Q1 2025: $2.81 million | Q2 2025: $2.17 million | Q3 2025: $1.52 million.
- Over the full 6 years of available data (2020 to 2025), Indaptus Therapeutics, Inc.'s Research And Development Expense has grown by 251.8%.
- Historical annual values: Fiscal year 2025: $9.34 million | Fiscal year 2024: $7.25 million | Fiscal year 2023: $7.62 million | Fiscal year 2022: $6.32 million | Fiscal year 2021: $2.52 million | Fiscal year 2020: $2.66 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: